Abstracts tagged "SLE"

Abstract Number: 3110 • 2016 ACR/ARHP Annual Meeting
Rab4A Is Required for Development of Tregs, Restricts Antiphospholipid Antibody Production and Pro-Inflammatory Expansion of Macrophages and Neutrophils, and Blocks Pristane-Induced Intra-Alveolar Hemorrhage in a Mouse Model of SLE
Zachary Oaks¹, Thomas Winans¹, Nick Huang¹, Sarah Blair¹, Miguel Beckford¹, Katalin Banki² and Andras Perl³, ¹SUNY, Syracuse, NY, ²Clinical Pathology, SUNY Upstate Medical University, Syracuse, NY, ³Department of Medicine, Upstate Medical University, Syracuse, NY
Background/Purpose: Polymorphic haplotypes of the HRES-1 endogenous retrovirus at the 1q42 chromosomal locus have been associated with lupus susceptibility, in particular, with predisposition to antiphospholipid…
Abstract Number: 759 • 2016 ACR/ARHP Annual Meeting
Gene Signature for Glucocorticoid, from in Vitro to In Vivo
Yanhua Sarah Hu¹, Somnath Bandyopadhyay¹, Deborah Furst¹, A Johnsen¹, Robert Latek¹, Steven G. Nadler² and Julie Carman³, ¹Bristol-Myers Squibb, Princeton, NJ, ²Immunosciences Translational Research, Bristol-Myers Squibb, Princeton, NJ, ³Discovery Translational Sciences Group, Bristol-Myers Squibb, Princeton, NJ
Background/Purpose: Steroids are widely used in clinical practice for treating systemic lupus erythematosus (SLE), and can have a strong effect on immune cells in Whole…
Abstract Number: 1048 • 2016 ACR/ARHP Annual Meeting
Differences in Clinical Manifestations of SLE Across Four Racial/Ethnic Groups: The California Lupus Surveillance Project (CLSP)
Ernest Maningding¹, Jinoos Yazdany², Laura Trupin², Chris Tonner³, Charles G. Helmick⁴ and Maria Dall'Era⁵, ¹Internal Medicine, Santa Clara Valley Medical Center, San Jose, CA, ²Medicine/Rheumatology, University of California, San Francisco, San Francisco, CA, ³Rheumatology, University of California, San Francisco, San Francisco, CA, ⁴CDC, Atlanta, GA, ⁵Division of Rheumatology, University of California, San Francisco, San Francisco, CA
Background/Purpose: The CLSP is a population-based registry of individuals with SLE residing in San Francisco County, California from 2007 – 2009. The registry has a…
Abstract Number: 1755 • 2016 ACR/ARHP Annual Meeting
Dendritic Cell-Specific Loss of Caspase 8 Incites Symptoms of Neuropsychiatric Systemic Lupus Erythematosus
Hadijat Makinde¹, Harris R. Perlman² and Carla Cuda¹, ¹Northwestern University, Chicago, IL, ²Department of Medicine, Division of Rheumatology, Northwestern University Feinberg School of Medicine, Northwestern University, Chicago, IL
Background/Purpose: Previous studies implicate dendritic cells (DCs) in the initiation and persistence of systemic lupus erythematosus (SLE), and although DCs from SLE patients exhibit elevated…
Abstract Number: 1969 • 2016 ACR/ARHP Annual Meeting
Peer Approaches to Lupus Self-Management (PALS): A Novel Lupus Peer Mentorship Intervention
Edith M. Williams¹, Leonard Egede², Jim Oates³, Delia Voronca² and Mulugeta Gebregziabher², ¹Public Health Sciences, Medical University of South Carolina, Charleston, SC, ²Medical University of South Carolina, Charleston, SC, ³Medicine/Rheumatology & Immunology, Medical University of South Carolina, Charleston, SC
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a chronic autoimmune disease that is associated with increased morbidity, mortality, health care costs and decreased quality of life.…
Abstract Number: 2851 • 2016 ACR/ARHP Annual Meeting
An Antigen Microarray to Rule-out Systemic Lupus Erythematosus, the SLE-Key® Rule-out Test, Performs Well As an Aid in Clinical Practice
Donald Massenburg, Justine Oldenberg, Amanda Sell, Tristan Krause and Alvin F. Wells, Rheumatology and Immunotherapy Center, Franklin, WI
Background/Purpose: The SLE-key® test to Rule Out lupus was developed by ImmunArray Ltd using serum samples of 246 SLE patients and 252 self-declared healthy controls.…
Abstract Number: 3172 • 2016 ACR/ARHP Annual Meeting
Temporal Trends in SLE Mortality According to Sex, Race, Ethnicity, and Geographic Region in the United States over the Past Five Decades
Eric Yen¹, Magda Shaheen², Jennifer MP Woo¹, Neil Mercer¹, Lewei Duan¹, Ning Li¹, Arun Karlamangla¹, Deborah K. McCurdy¹ and Ram R. Singh¹, ¹UCLA, Los Angeles, CA, ²Charles R. Drew University of Medicine and Science, Los Angeles, CO
Background/Purpose: Over the past half-century, diagnostic and therapeutic developments for SLE have led to dramatic improvements in the 5- and 10-year survival. Whether these achievements…
Abstract Number: 763 • 2016 ACR/ARHP Annual Meeting
Rituximab As a Corticosteroid-Sparing Agent in Patients with Systemic Lupus Erythematosus
Na Ri Kim¹, Jung Su Eun¹, Jong Wan Kang¹, Eon Jeong Nam¹ and Young Mo Kang², ¹Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, South Korea, ²Division of Rheumatology, Department of Internal Medicine, Kyungpook National University School of Medicine, Daegu, Korea, Republic of
Background/Purpose : The treatment of active systemic lupus erythematosus (SLE) remains problematic because the current treatment regimen based on corticosteroids and immunosuppressive agents have significant…
Abstract Number: 1053 • 2016 ACR/ARHP Annual Meeting
Evaluating the Charla De Lupus (Lupus Chat)® Program’s Teen, Young Adult and Parent Support Group: Reaching the Hispanic/Latino Community through a Family Model of Support
Melissa T. Flores¹, Jillian A. Rose², Priscilla Toral¹, Roberta Horton¹, Dariana M. Pichardo¹, Lillian Mendez¹ and Lisa F. Imundo³, ¹Social Work Programs, Hospital for Special Surgery, New York, NY, ²Hospital for Special Surgery, New York, NY, ³Assoociate Professor of Pediatrics in Medicine - Rheumatology, Columbia University Medical Center, New York, NY
Background/Purpose: Research shows that chronic illnesses such as SLE have multi-level impact on the family; it can be challenging for both patients & caregivers to…
Abstract Number: 1765 • 2016 ACR/ARHP Annual Meeting
Minimal Clinically Important Differences for Generic Patient Reported Outcomes Tools in SLE
Hervé Devilliers¹, Narender Annapureddy² and Meenakshi Jolly³, ¹Department of Internal Medicine and Systemic Diseases, Hôpital François Mitterrand, CHU de Dijon, Dijon, France, ²Rheumatology and Immunology, Vanderbilt University, Nashville, TN, ³Department of Medicine, Section of Rheumatology, Rush University Medical Center, Chicago, IL
Background/Purpose: Patients with Systemic lupus erythematosus (SLE) have significant impairment in quality of life (QOL). Health related QOL (HRQOL) is one of the four established…
Abstract Number: 2059 • 2016 ACR/ARHP Annual Meeting
Serine/Arginine-Rich Splicing Factor 1 (SRSF1) Is a Novel Factor in T Cell Homeostasis and Its Selective Loss in T Cells Causes Autoimmunity and Lupus-like Nephritis
Vaishali R. Moulton¹, Hao Li², Michael W. Mosho², Andrew R. Gillooly², Meghan L. Keane³ and George C. Tsokos⁴, ¹Division of Rheumatology, Department of Medicine, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ²Medicine/ Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ³Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, ⁴Division of Rheumatology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA
Background/Purpose: T cells from patients with systemic lupus erythematosus (SLE) express reduced amounts of the critical CD3 zeta signaling chain, and produce low levels of…
Abstract Number: 2857 • 2016 ACR/ARHP Annual Meeting
Results from a Phase 0 Longitudinal Clinical Trial in Cutaneous Lupus Erythematosus: Analysis of the Type I IFN Signature in the Skin and Blood and Its Relationship with Disease Activity Scores and Autoantibody Profiles
Jessica Schreiter¹, Jarrat Jordan¹, Matteo Cesaroni¹, Marc Chevrier², Alexa Piantone³, Ian Gourley³, Jacqueline Benson¹ and Takahiro Sato¹, ¹Estrela Lupus Venture, Janssen Research and Development, LLC., Spring House, PA, ²Janssen Research and Development, LLC, Collegeville, PA, ³Immunology Translational Medicine, Janssen Pharmaceutical Research and Development, LLC, Spring House, PA
Background/Purpose: Type I IFN (IFN-I)-regulated gene expression is known to be elevated in blood and skin lesions of patients with two different forms of cutaneous…
Abstract Number: 3191 • 2016 ACR/ARHP Annual Meeting
Coronary Revascularization Procedure Rates and Risks Among Patients with Systemic Lupus Erythematosus Compared to Those with Diabetes Mellitus in a Nationwide Medicaid Cohort
Medha Barbhaiya¹, Candace H. Feldman¹, Sarah K. Chen², Hongshu Guan³, Tzu-Chieh Lin¹, Michael A. Fischer⁴, Daniel H. Solomon⁵, Brendan M. Everett⁶ and Karen H. Costenbader¹, ¹Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ²Beth Israel Deaconess Medical Center, Boston, MA, ³Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁴Division of Pharmacoepidemiology and Pharmacoeconomics, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁵Division of Rheumatology, Brigham and Women's Hospital and Harvard Medical School, Boston, MA, ⁶Division of Cardiovascular Medicine, Brigham and Women's Hospital and Harvard Medical School, Boston, MA
Background/Purpose : We have recently found that myocardial infarction (MI) risk was similar among age- and sex-matched SLE patients compared to diabetes mellitus (DM) patients…
Abstract Number: 767 • 2016 ACR/ARHP Annual Meeting
Hydroxychloroquine Induced Retinopathy in SLE
Michelle Petri¹ and Wei Fu², ¹Rheumatology Division, Johns Hopkins University School of Medicine, Baltimore, MD, ²Rheumatology, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Retinal toxicity from hydroxychloroquine (HCQ), has been recognized for many years. But poor compliance of HCQ might confound results of previous studies. Therefore, we…
Abstract Number: 1083 • 2016 ACR/ARHP Annual Meeting
Discovery and Subsequent Diagnostic Verification of Autoantibodies Against the Major Vault Protein (MVP) in Systemic Lupus Erythematosus
Petra Budde¹, Johannes Schulte-Pelkum¹, Daniel Wirtz¹, Hans-Dieter Zucht¹, Heike Göhler¹, Stefan Vordenbäumen², Peter Schulz-Knappe¹ and Matthias Schneider³, ¹Protagen AG, Dortmund, Germany, ²Rheumatology, Heinrich-Heine-University Düsseldorf, Düsseldorf, Germany, ³Rheumatology, Heinrich-Heine-University, Duesseldorf, Germany
Background/Purpose: In systemic lupus erythematosus (SLE), early diagnosis and prognostic stratification are still great challenges. The broad characterization of the autoantibody repertoire in SLE is…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].